$8.89-1.09 (-10.92%)
Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.89. The stock is currently 46% below its 52-week high of $16.34, remaining 41.1% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why ARMP maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after […]
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?